GAIA 251
Alternative Names: GAIA-251Latest Information Update: 14 Feb 2022
Price :
$50 *
At a glance
- Originator GAIA BioMedicine
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements; Gene transference; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Feb 2022 GAIA BioMedicine has patent protection for GAIA NK-like cells (GAIA BioMedicine website, February 2022)
- 01 Feb 2022 Early research in Cancer (IV) (GAIA BioMedicine pipeline, February 2022)
- 01 Feb 2022 Early research in Cancer in Japan (IV) (GAIA BioMedicine pipeline, February 2022)